Cargando…
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Patients with neurofibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNs), which can cause significant morbidity. We performed a phase II trial of the MAPK/ERK kinase inhibitor, mirdametinib (PD-0325901), in patients with NF1 and inoperable PNs. The primary objective was response...
Autores principales: | Weiss, Brian D., Wolters, Pamela L., Plotkin, Scott R., Widemann, Brigitte C., Tonsgard, James H., Blakeley, Jaishri, Allen, Jeffrey C., Schorry, Elizabeth, Korf, Bruce, Robison, Nathan J., Goldman, Stewart, Vinks, Alexander A., Emoto, Chie, Fukuda, Tsuyoshi, Robinson, Coretta T., Cutter, Gary, Edwards, Lloyd, Dombi, Eva, Ratner, Nancy, Packer, Roger, Fisher, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078274/ https://www.ncbi.nlm.nih.gov/pubmed/33507822 http://dx.doi.org/10.1200/JCO.20.02220 |
Ejemplares similares
-
NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM
por: Mueller, Sabine, et al.
Publicado: (2020) -
Clinical trial design for cutaneous neurofibromas
por: Cannon, Ashley, et al.
Publicado: (2018) -
Giant scalp plexiform neurofibroma associated with NF-1
por: Munakomi, Sunil
Publicado: (2017) -
Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment
por: Kershner, Leah J., et al.
Publicado: (2022) -
A molecular basis for neurofibroma-associated skeletal manifestations in NF1
por: Ma, Yun, et al.
Publicado: (2020)